Advertisement
Canada markets open in 50 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7274
    +0.0011 (+0.15%)
     

  • CRUDE OIL

    82.23
    -0.50 (-0.60%)
     

  • Bitcoin CAD

    89,627.81
    +4,579.51 (+5.38%)
     

  • CMC Crypto 200

    1,343.04
    +30.42 (+2.37%)
     

  • GOLD FUTURES

    2,396.60
    -1.40 (-0.06%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.5900
    -0.0570 (-1.23%)
     

  • NASDAQ futures

    17,531.25
    -16.00 (-0.09%)
     

  • VOLATILITY

    18.68
    +0.68 (+3.78%)
     

  • FTSE

    7,840.48
    -36.57 (-0.46%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6815
    -0.0006 (-0.09%)
     
MARKETS LIVE BLOG:

STOCK FUTURES DIG OUT OF ISRAEL STRIKE-FUELLED TUMBLE

Shares of Netflix, the first of the megacap techs to report, slide in pre-market trading

Gilead Sciences Stock: How Much Upside Do Analysts Expect?

Kenneth Smith
Updated
Gilead Sciences Stock: How Much Upside Do Analysts Expect?

Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

Continue reading